Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Assets (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Non-Current Assets for 8 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 22.02% year-over-year to $29.7 million, compared with a TTM value of $150.6 million through Dec 2025, down 7.37%, and an annual FY2025 reading of $29.7 million, down 22.02% over the prior year.
  • Non-Current Assets was $29.7 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $33.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $64.4 million in Q3 2023 and bottomed at $10.8 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $35.8 million, with a median of $40.7 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 322.36% in 2022, then plummeted 38.13% in 2024.
  • Year by year, Non-Current Assets stood at $13.9 million in 2021, then soared by 239.67% to $47.1 million in 2022, then dropped by 9.02% to $42.8 million in 2023, then fell by 11.03% to $38.1 million in 2024, then fell by 22.02% to $29.7 million in 2025.
  • Business Quant data shows Non-Current Assets for ARCT at $29.7 million in Q4 2025, $33.1 million in Q3 2025, and $34.8 million in Q2 2025.